| Characteristics |
Cases
N=154(%) |
Wild type
TT
N=114(%) |
Heterozygous
TG
N=38(%) |
Homo mutant
GG
N=2(%) |
P-Value |
Age of Diagnosis
21-30
31-40
41-50
51-60
61-70 |
16(10%)
38(25%)
50(32%)
38(25%)
12(8%) |
10(63%)
22(58%)
42(84%)
28(74%)
12(100%) |
6(37%)
14(37%)
8(16%)
10(26%)
0(0%) |
0(0%)
2(5%)
0(0%)
0(0%)
0(0%) |
0.22
0.03
0.07
0.82
0.12 |
Body mass index(BMI) status
Normal weight >18.50 to <24.99
Overweight >25 to <29.99
Obese >30.00 |
30(19%)
40(26%)
84(55%) |
20(67%)
29(73%)
65(86%) |
9(30%)
11(27%)
18(14%) |
1(3%)
0(0%)
1(0%) |
0.17
0.38
0.06 |
Age at Menarche
11-12
13-14
15-16 |
52(34%)
84(54%)
18(12%) |
37(71%)
64(76%)
13(72%) |
13(25%)
20(24%)
5(28%) |
2(4%)
0(0%)
0(0%) |
0.84
0.70
0.77 |
Menopausal Status
Post Menopausal
Pre Menopausal |
80(52%)
74(48%) |
65(81%)
49(66%) |
15(19%)
23(31%) |
0(0%)
2(3%) |
0.06
0.06 |
Estrogen Receptor status
ER+ /PR+
ER+/PR-
ER-/PR+
ER-/PR- |
48(31%)
10(7%)
6(4%)
90(58%) |
38(79%)
4(40%)
6(100%)
66(73%) |
10(21%)
6(60%)
0(0%)
22(25%) |
0(0%)
0(0%)
0(0%)
2(2%) |
0.42
0.01
0.30
1.00 |
Her2 status
Her2+
Her2- |
135(88%)
19(12%) |
100(74%)
14(74%) |
33(24%)
5(26%) |
2(2%)
0(0%) |
0.88
0.88 |
Chemotherapy
5FU,Adriamycin,Endoxane
Hormonal therapy
RD
No Data |
108(70%)
11(7%)
28(18%)
7(5%) |
84(78%)
9(82%)
15(54%)
6(86%) |
22(20%)
2(18%)
13(46%)
1(14%) |
2(2%)
0(0%)
0(0%)
0(0%) |
0.06
0.59
0.005
0.51 |
